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Background. Lentiviral constructs reportedly can integrate into the genome of non-dividing, terminally diﬀerentiated cells and
dividing cells, for long-term gene expression. This investigation tested whether a third generation lentiviral-mediated small
interferingRNA(siRNA)deliveredintorenalepithelialandﬁbroblastcellsagainsttypeIItransforminggrowthfactor-betareceptor
(siRNA-TBRII) could better attenuate renal ﬁbrogenesis in comparison with a non-lentiviral construct. Methods.H I V - d e r i v e d
lentiviral and non-lentiviral constructs were used to transfect cells with siRNA-TBRII or siRNA-EGFP control. Human embryonic
kidney (HEK-293T), renal epithelial cells (NRK-52E) and renal ﬁbroblasts (NRK-49F) were transfected and gene silencing
quantiﬁed (ﬂuorescence microscopy, Western blotting, ﬂuorescence-activated cell sorting). Renal ﬁbrogenesis was assessed using
extracellular matrix protein synthesis (ﬁbronectin and collagen-III; Western immunoblot), and α-smooth muscle actin (α-
SMA) was analysed as a marker of ﬁbroblast activation and epithelial-to-mesenchymal transdiﬀerentiation (EMT). Results.
Lentiviral-mediated siRNA-TBRII signiﬁcantly suppressed TBRII expression in all cell lines, and also signiﬁcantly suppressed
renal ﬁbrogenesis. In comparison with the non-lentiviral construct, lentiviral-mediated siRNA-TBRII produced stronger and
more persistent inhibition of collagen-III in NRK-49F cells, ﬁbronectin in all renal cell lines, and α-SMA in renal epithelial
cells. Conclusions. Lentiviral vector systems against TBRII can be delivered into renal cells to eﬃciently limit renal ﬁbrogenesis
by sequence-speciﬁc gene silencing.
1.Background
Tubulointerstitial ﬁbrosis is an almost invariable ﬁnding in
the chronically diseased kidney, irrespective of the under-
lying disease or the originating compartment. The degree
of ﬁbrosis, determined by the relative interstitial volume
caused by accumulation of extracellular matrix (ECM), is an
importantpredictoroforganprognosisandkidneyexcretory
function [1]. Renal tubulointerstitial ﬁbrosis is believed to
be the ﬁnal common pathway for nearly all forms of kidney
disease that progress towards end-stage renal disease [2].
Transforming growth factor-β (TGF-β), a protein reg-
ulator of cell growth and diﬀerentiation, is one of the
primary mediators that induces accumulation of ECM in
renal ﬁbrogenesis [3, 4]. TGF-β increases the production
anddepositionofECMproteins,reducesmatrixdegradation
through decreased proteinase production and increased
production of matrix degradation inhibitors, and stimulates
synthesis of ECM protein receptors [5]. Upregulation of
TGF-β is a universal ﬁnding in virtuallyevery type of chronic
kidneydisease,inanimalmodelsandinhumans[4].Invitro,
TGF-β alone can stimulate mesangial cells and interstitial2 Journal of Biomedicine and Biotechnology
ﬁbroblasts to produce ECM and tubular epithelial cells to
undergo epithelial-to-mesenchymal transformation (EMT)
to become matrix-producing ﬁbroblast-like cells. Expression
of exogenous TGF-β, either via gene delivery in vivo or in
transgenic mice, causes renal ﬁbrosis [6]. TGF-β binds to
speciﬁc receptors on most cells including renal epithelial and
ﬁbroblast cells and then initiates a signal cascade that results
in production of proﬁbrotic cytokines and inﬂammatory
mediators.ThetypeIandtypeIIsignallingreceptorsmediate
the biological actions of TGF-β. The extracellular domain
of the type II receptor (TBRII) binds TGF-β, causing the
formation of heteromeric complexes [7, 8]. TBRII then
transphosphorylates the type I receptor, activates its kinase,
and initiates downstream signalling. In this respect, the
TBRII appears to be essential for the biological activity of
TGF-β signalling pathway [9], and its inhibition or modiﬁ-
cation is considered as a promising therapeutic strategy to
inhibit renal ﬁbrosis.
Modulation of TGF-β action on ECM suppresses tissue
ﬁbrosis [2, 10]. For example, biological inhibition of TGF-
β protein with neutralising antibodies [11], decorin [12,
13], and soluble TBRII-IgG Fc chimera [14] suppressed the
accumulation of ECM in models of renal ﬁbrosis. Other
studies have shown that expression of soluble TBRII could
eﬀectively block TGF-β signalling in vitro and in vivo, using
various means of delivery [15, 16]. However, the methods
used in previous studies have therapeutic limitations because
the protein or gene is rapidly degraded by enzymes after
administration in vivo [17, 18]. The short-term duration
of TGF-β signalling inhibition is a major problem to be
solved.
Lentiviral vectors can infect non-dividing cells, can
be pseudotyped with retroviral envelopes, and so have a
broad cell tropism, have no toxic eﬀect, and have stable
gene expression due to viral genome integration into cell
chromosomes [19]. Despite having many of the same
characteristics, retroviral vector-mediated gene therapies or
nonviral vector-mediated gene deliveries have a limited or
transient eﬀect and can infect only dividing cells [19].
Melding the lentiviral vector-mediated gene delivery and
the powerful tool of RNA inhibition (RNAi) could poten-
tially provide targeted long-term gene silencing. RNAi is a
mechanism for sequence-speciﬁc, posttranscriptional gene
silencing triggered by double-strand RNA (dsRNA; referred
to as small interfering RNA, silencing RNA or siRNA), which
targets the degradation of complementary mRNAs [20].
The siRNA mediators of RNAi typically consist of 19–23
nucleotide RNA duplexes. During RNAi, the introduction of
siRNA by transfection into a diverse range of organisms and
cell types causes degradation of the complementary mRNA,
thereby silencing gene expression.
Because of the ability of lentiviral vectors to deliver
transgenes into tissues that are considered resistant to stable
genetic manipulation, like well-diﬀerentiated adult renal cell
populations with limited levels of mitosis, new possibilities
for gene therapy are opening. Gusella et al. [21] successfully
transduced a 1st-generation lentiviral vector into mouse
kidneys. The current study used a cell culture model of renal
ﬁbrosis to compare the eﬃciency to limit renal ﬁbrogenesis
and the durability of expression of a lentiviral versus a
nonlentiviral versus a lentiviral-delivered siRNA to TBRII
(siRNA-TBRII).
2. Methods
2.1. Cell Culture. Rat renal epithelial (NRK-52E, ATCC
CRL1571) and ﬁbroblast (NRK-49F, ATCC CRL1570) cell
lines were selected for comparison of ﬁbrogenesis. Human
embryonic kidney- (HEK-) 293T cells, a derivative of the
HEK-293 cell line (ATCC CRL1573) were selected for
plasmid transfection and lentiviral vector transduction. An
enhanced greenﬂuorescent protein (EGFP) stably expressing
HEK-293T cell line (S7 cells, established at Dr. Ming
Wei’s laboratory, Department of Medicine, Prince Charles
Hospital, University of Queensland, Brisbane, Australia) was
used for transfection to evaluate the silencing eﬀect on EGFP
by RNAi.
NRK-49F and NRK-52E cells were maintained routinely
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% bovine calf serum (BCS), 1,000 units per
millilitre (U/mL) penicillin, and 1,000μg/mL streptomycin
(BioWhittaker,EdwardKellerPtyLtd,Silverwater,Australia).
For HEK-293T cells and the EGFP stably expressing S7 cells,
DMEM was supplemented with 10% fetal calf serum (FCS).
Cells were grown in a humidiﬁed atmosphere of 95% air
and 5% carbon dioxide at 37◦C in a tissue culture incubator.
The original cell seeding density was of 2–5 × 105 cells per
mL. Cells were grown for 24–48 hours prior to treatment
or until just subconﬂuent. Prior to treatment, all cells
were washed twice in serum-free (SF) DMEM containing
antibioticsonly,toremoveanytracesofserumgrowthfactors
or supplements.
2.2. PCR Cloning and Plasmid Preparations. A 444bp extra-
cellular ectodomain including the critical soluble TBRII
TGF-β binding domain comprising the amino acid DNA
sequence from 284bp to 727bp (targeting the sequence
between starting codon and the beginning of hydrophobic
trans-membrane spanning domain) of Rattus norvegicus
TBRII mRNA (Genbank s67770) [22]w a sg e n e r a t e db y
reverse transcriptase PCR from normal rat kidney cDNA
using a QIAGEN Taq PCR core kit. The 444bp DNA
sequenceoftheTBRIIgenewasligatedintothepDrivevector
(QIAGEN, Australia) at a molar ratio of 5–10 times more
PCR product DNA than pDrive cloning vector DNA. The
orientation of PCR product in the recombinant plasmid was
conﬁrmed by restriction enzyme digestion. After enzyme
digestion, the recombinant plasmid pDrive-TBRII with the
PCR insert of the 444bp soluble domain of the TBRII gene
was mini-preped using a GenElute Plasmid Miniprep Kit
(Sigma-Aldrich, Australia) and maxi-preped for a larger
amount of plasmid production using a Plasmid Maxi Kit
(QIAGEN, Australia). The constructed pDrive-TBRII with
its PCR insert was further conﬁrmed by DNA sequencing at
the Australian Genome Research Facility (Gehrmann Labo-
ratories,UniversityofQueensland,http://www.agrf.org.au/).Journal of Biomedicine and Biotechnology 3
2.3. Preparation of RNAi Expression Plasmids. Two
complementary oligonucleotides necessary to create the
hairpin insert for pPlasRi cloning vectors were designed
following a software siRNA Wizard v2.5 available on
line at http://www.sirnawizard.com/. The sequences
of custom-designed oligonucleotides were as follows:
TBRII RNAi short hairpin (sh) insert “A” targeting the
ﬁrst 100bp starting from ATG start codon: 5
 -GAT
CCC C ACGTTCCCAAGTCGGTTAA TT C AA G AG A
TTAACCGACTTGGGAACGT TTT TTG GAA A-3
  and
5
 - TCGA TT TCC AAA AA ACGTTCCCAAGTCGGTTAA
TCT CTT GAA TTAACCGACTTGGGAACGT GG G-3
 ,
insert “B” targeting the last 100bp of codons of TBRII:
5
 -GAT CCC C AGATTCCAGAAGACGGCTC TT C AA G A
GA GAGCCGTCTTCTGGAATCT TTT TTG GAA A-3
  and
5
 -TCGA TT TCC AAA AA AGATTCCAGAAGACGGCTC
TCT CTT GAA GAGCCGTCTTCTGGAATCT GG G-3
 .
The 19-nucleotide TBRII target sequences are underlined
in these sequences. Two single-strand oligonucleotides
synthesised for EGFP and used as experimental control
siRNA were provided by Dr. Ming Q. Wei (one of the
authors). All oligos were purchased in a lyophilised desalted
form from Sigma Genosys Australia (Castle Hill, Australia).
A pair of oligonucleotides was annealed using the methods
previously described [23]. After annealing of two-single
stranded oligos into double-stranded inserts, siTBRII and
siEGFP were ligated to linearised pPlasRi plasmid (provided
by Dr. Ming Q. Wei, one of the authors) that contains the
human H1 RNA Polymerase III promoter after BglII and SalI
digestion. Compatible enzyme sequences were synthesized
at both ends of annealed oligos. Both siTBRII inserts showed
eﬃcient silencing eﬀe c ta tt h ep r o o fo fc o n c e p te x p e r i m e n t ,
and the pair targeting the ﬁst 100bp was used in this study.
Inaddition, pPlasRiwithoutanyinsertion ofoligonucleotide
(empty pPlasRi) was used as a negative control.
2.4. Production of Lentiviral RNAi Constructs. The third-
generation replication-defective HIV-1-based lentiviral vec-
tor pHIV-CS (7488bp) was provided by Dr. Ming Q. Wei,
one of the authors. Both lentiviral RNAi constructs (pLenti-
TBRII and pLenti-EGFP) were constructed by cloning
the pHIV-CS backbone with siRNA inserts derived from
pPlasRi-RBRII or pPlasRi-EGFP by BamHI and XhoI diges-
tion, in which the RNA promoter was also transferred to the
lentiviral RNAi plasmids.
2.5. Lentiviral Construct Transfection In Vitro. For in vitro
transfection, 1 × 105 cells were seeded per well in 12-well
plates 16–18 hours before the experiment, by which time the
cellsreached75–80% conﬂuence.PlasmidsDNAof2μgwith
a linear PEI derivative (ExGen 500 MBI Fermentas, Hanover
MD, USA), at N/P ratio of 1:6 to 1:9, were incubated for
10 minutes at room temperature and then added to the
wells. The transfection medium containing plasmid DNA
was replaced 8 hours later with fresh growth medium and
cells were further incubated for 16 hours or longer for up to
72 hours as required.
2.6. FACS Quantiﬁcation of EGFP Expression. EGFP gene
expression wasanalysedby direct ﬂuorescenceusing aconfo-
cal microscope (Queensland Institute for Medical Research,
Brisbane), and images were digitised. Fluorescence-activated
cell sorting (FACS; Becton Dickinson and Co, Franklin
Lakes NJ, USA) was performed using 10,000 ﬁxed cells at
various intervals after transfection to quantify the number
and the mean ﬂuorescence intensity of cells positive for
EGFP. Untransfected HEK-293T and S7 cells were used to
determine the cutoﬀ values. Gene silencing eﬀectiveness
was evaluated by direct visualization under a ﬂuorescent
microscope (in the stably EGFP-expressing S7 cells which
were transfected by EGFP RNAi plasmids) and quantiﬁed
by FACS. Immunoﬂuorescence (IF) microscopy or Western
immunoblot was used for protein analysis of TBRII in NRK-
49F and NRK-52E cells which were transfected by TBRII
RNAi plasmids.
2.7. Immunoﬂuorescence. For IF staining of TBRII on trans-
fected HEK-293T cells, cells on coverslips were washed and
ﬁxed, and then nonspeciﬁc binding was blocked with 3%
bovine serum albumin in Tris-buﬀered saline with Tween-
20 (BSA in TBST) for 1 hr at room temperature. Coverslips
were incubated with primary antibody against TBRII (TGFβ
RII, 1:10, Santa Cruz) for 1 hour at room temperature
(RT). Sections were washed 3 × 30 minutes in TBST, then
incubated with a ﬂuorescent secondary antibody mixture
containing an FITC-labelled goat antirabbit IgG (Molecular
Probes, Oregon, USA) at a dilution of 1:200 in 1% BSA in
T B S Tf o r1h o u ra tR Ti nad a r kc u p b o a r d .C o v e r s l i p sw e r e
washed 3 × 30 minutes in TBST, then mounted onto glass
slides using DAKO antifade ﬂuorescence mounting medium
(DAKO, Australia), and allowed to set overnight in the dark
at 4◦C or over 2–3 hours at RT prior to confocal ﬂuorescence
microscopy.
2.8. Western Immunoblot. Cells were disrupted in ice-cold
cell lysis buﬀer (50mM Tris-Cl at pH 7.5, 150mM NaCl,
1% Nonidet P-40, 0.1% sodium dodecyl sulphate (SDS),
25mM sodium ﬂuoride, and 0.5M ethylenediamine tetra-
acetic acid) containing protease and phosphatase inhibitors
(100μg/mL phenylmethylsulfonyl chloride, 20μg/mL leu-
peptin, 20μg/mL aprotinin, and 1mM sodium orthovana-
date, all Sigma-Aldrich products) using a tissue homoge-
nizer. Cell debris was removed by centrifugation at 16000g
for15minutesat4◦C.Proteinconcentrationwasdetermined
in each extract by a Bradford protein assay (Bio-Rad Pty Ltd,
Sydney, NSW, Australia) and spectroscopy at 595nm. 30μg
of total protein were loaded onto 12% SDS polyacrylamide
gel, run at 100V with a set current of 60mAmps for 1.75
hours, and then transferred to a polyscreen polyvinylidene
diﬂuoride membrane (Perkin Elmer, Melbourne, Australia)
using a Bio-Rad Mini Protean 3 unit (Bio-Rad, Australia).
Nonspeciﬁc binding of antibodies to the membrane was
blocked by incubation in 4% skim milk powder in TBST
buﬀer (blotto) for 1 hour with continuous rocking. Anti-
bodies were added to blotto or 0.1% BSA in TBST (primary4 Journal of Biomedicine and Biotechnology
antibody TGFβ RII Mouse mAb) and incubated with mem-
branes overnight at 4◦C on a rocking platform. Blots were
washed repeatedly (4–5 times, 5–10 minutes each) in TBST
and then incubated with the corresponding Horseradish
peroxidase- (HRP-) conjugated secondary antibody (rabbit-
α-mouse IgG-HRP) diluted in either 4% blotto or 0.1%
BSA in TBST for 1 hour at RT on a rocking platform.
Membranes were subjected to a second stage of vigorous
and stringent washes (4-5) in TBST containing 0.1% Igepal
CA-630, each for 5-minute duration. Membranes were
incubated with SuperSignal West Pico chemiluminescent
substrate (Pierce Biotechnology, Rockford, IL, USA) for 2
minutes with vigorous shaking. Protein bands were detected
using enhanced chemiluminescence (ECL) imaging onto X-
ray ﬁlm (Kodak X-Omat AR-5 or Fuji Rx XR Film) and
scanned using a Hewlett-Packard ScanJet 3200C at 300dpi.
Scion Image software (vβ4.0.2) was used to quantify the
densityofproteinbandsminuslocalbackgroundinarbitrary
densitometry units. All protein bands were normalised
against actin, or membranes were stained with Coomassie
Brilliant Blue (Sigma-Aldrich: catalogue number B7920) to
verify equal protein loading of lanes. Cell extract positive
controls from antibody suppliers were routinely used for
immunoblots.
2.9. Statistical Analysis. Data were analysed using standard
statistical methods, linear regression, Students, t-test, one-
way analysis of variance (ANOVA), and Tukey’s, Dunnett’s
multiplecomparison,orBonferroniposttestusingGraphpad
Prism (version 3.0) and Stata (version 8.0) statistical soft-
ware. Most data are presented in graphic form as the means
± SEM. Signiﬁcance was assessed at P<. 05.
3. Results
3.1. RNAi Expression Constructs for TBRII and EGFP. TBRII
and EGFP RNAi expression constructs were constructed
ﬁrst, followed by the lentiviral RNAi construct. EGFP was
used as a reporter gene. The RNAi eﬀect was ﬁrst tested
by transfection of the expression plasmids in vitro before
moving onto Lenti-RNAi plasmid construction. Once the
gene silencing eﬀect was conﬁrmed, RNAi cassettes together
with the upstream RNA promoter were transferred into
a third-generation HIV-1 based lentiviral plasmid. Two
single-stranded oligonucleotides synthesised for TBRII and
EGFP siRNA were annealed to be double-stranded inserts.
Constructed RNAi expression plasmids pPlasRi-TBRII and
pPlasRi-EGFP were conﬁrmed by restriction digestion.
3.2. Inhibition of EGFP by RNAi Expression Construct and
Lentiviral RNAi Construct In Vitro. EGFP RNAi expres-
sion construct pPlasRi-EGFP and lentiviral RNAi construct
pLentiRi-EGFP were transfected into S7 cells, facilitated by
the cationic polymer PEI. Silencing of EGFP expression
by RNAi was evaluated by counting numbers of green
ﬂuorescent cells by FACS analysis at 24 hours, 48 hours,
and 72 hours post transfection. Empty pPlasRi and pLentiRi
constructs without RNAi insert were used as negative con-
trols. These results are demonstrated in Figure 1. There was
78.28%, 69.37%, and 40.09% inhibition of EGFP expression
(P<. 001) as measured by FACS at 24, 48, and 72 hours,
respectively, post transfection of pPlasRi-EGFP into S7 cells.
The negative control group did not show EGFP inhibition.
The RNAi expression construct pPlasRi-EGFP gene silencing
eﬀect was however transient, peaking at 24 hours, and
then starting to diminish. In comparison, persistent EGFP
inhibition up to 72 hours was observed postlentiviral RNAi
construct pLentiRi-EGFP transfection, with an 84.17%,
91.57%, and 95.91% decrease of EGFP expression achieved
at 24, 48, and 72 hours, respectively, and EGFP silencing
eﬀect by lentiviral construct increased with time. There
was no signiﬁcant diﬀerence in gene silencing eﬀect when
comparing the transfection of the two constructs at 24
hours.ThelentiviralRNAiconstruct,however,demonstrated
signiﬁcant advantages in posttranscriptional gene silencing
than the expression construct at 48 and 72 hours. No EGFP
inhibition was observed in the negative control group.
3.3. Posttranscriptional Sequence-Speciﬁc Gene Silencing of
TBRII by RNAi In Vitro. Having proven successful EGFP
gene silencing by RNAi-expressing and lentiviral-RNAi
constructs in S7 cells, RNAi gene silencing of TBRII was
evaluated in renal epithelial and ﬁbroblast cell lines (NRK-
52E and NRK-49F) in vitro. An embryonic renal cell line
HEK-293T was also tested. Inhibition of ECM accumulation
in renal cells as a result of downregulation of TGF-β
signalling by RNAi was investigated.
3.4. TBRII Gene Suppression in HEK-293T by RNAi. TBRII
RNAi expression construct pPlasRi-TBRII and lentiviral
RNAi construct pLentiRi-TBRII were transfected into cul-
tured HEK-293T cells, facilitated by transfection agent PEI.
Inhibition of TBRII was examined by FITC-ﬂuorescence
immunohistochemistry and Western blot at 24, 48, and
72 hours. Empty pPlasRi and pLentiRi constructs without
RNAi insert were used as negative controls. Inhibition of
TBRII expression was observed after both pPlasRi-TBRII
and pLentiRi-TBRII transfection. TBRII inhibition in both
experimental groups persisted for up to 72 hours post-
transfection. pLentiRi-TBRII construct transfection showed
a signiﬁcantly stronger inhibition of TBRII when compared
to pPlasRi-TBRII at 72 hours (P<. 01). Gene silencing eﬀect
of lentiviral RNAi construct increased with time (P<. 01).
These results are shown in Figure 2.
3.5. TBRII Gene Suppression by RNAi in Renal Epithelial
and Fibroblast Cells. Having conﬁrmed the RNAi eﬀect in
HEK-293T cells post-transfection of both RNAi expression
construct and lentiviral RNAi construct, gene silencing
of TBRII was tested in renal epithelial (NRK-52E) and
ﬁbroblast (NRK-49F) cells. Expression of TBRII protein was
evaluated by Western blot analysis and semiquantiﬁed by
densitometry at 24, 48, and 72 hours post-transfection of
pPlasRi-TBRII and pLentiRi-TBRII. There was a signiﬁcant
decrease of TBRII expression in both cell lines at all testedJournal of Biomedicine and Biotechnology 5
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Figure 1: Gene silencing of EGFP by transfection of lentiviral and non-lentiviral expression constructs in vitro. RNAi EGFP gene silencing
was tested at 24, 48, and 72 hrs in EGFP stably expressing S7 cells post transfection of an EGFP-RNAi expression construct (pPlasRi-EGFP)
and a lentiviral RNAi construct (pLentiRi-EGFP). Fluorescence microscope images of cultured cells are demonstrated as well as the FACS
analysis. The percent of EGFP positive (+) cells (mean ± SEM) was assessed using FACS results, and these are shown graphically. There
was a signiﬁcant decrease of EGFP 24 hrs after both transfections compared to controls (∗∗P<. 01 in comparison with controls). The
pPlasRi-EGFP plasmid showed a transient silencing eﬀect in comparison with a persistent inhibition by the pLentiRi-EGFP, which produced
a continuing inhibition of EGFP (+) cells at 48 and 72 hrs. Gene silencing of EGFP by the pLentiRi-EGFP plasmid remained at 95.91% at
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Figure 2: Gene silencing of TBRII by RNAi in HEK-293T cells. pPlasRi-TBRII and pLentiRi-TBRII were transfected into HEK-293T cells.
FITC-ﬂuorescence immunohistochemistry of TBRII is demonstrated in the upper two panels. The upper panel demonstrates pPlasRi-
TBRII and the lower panel demonstrates pLentiRi-TBRII. Both groups showed a decrease of TBRII expression. TBRII was also evaluated by
Western blotting (blot panel) and semiquantiﬁed by densitometry (graphical presentation). There was signiﬁcant inhibition of TBRII after
both transfections at all time points (∗∗P<. 01 in comparison with controls), but the lentiviral construct increased with time and caused
signiﬁcantly greater silencing at 72 hrs than pPlasRi-TBRII (P<. 01).
time points. The lentiviral construct achieved a higher level
of inhibition and a longer time of gene silencing of TBRII in
bothrenalepithelialandﬁbroblastcelllines.Theseresultsare
demonstrated in Figure 3.
3.6. Inhibition of Fibrogenesis by TBRII RNAi in Renal Cells.
The biological eﬀect of TBRII RNAi should be reduced
ﬁbrogenesis, represented by reduced ECM production and
reduced EMT. Inhibition of ﬁbrogenesis was evaluated by
Western blotting in HEK-293T, NRK-52E, and NRK-49F
cells. Collagen III, ﬁbronectin (ECM production), and α-
SMA expression (EMT) were tested and semiquantiﬁed
by densitometry at 24, 48, and 72 hours posttransfec-
tion of the RNAi expression construct pPlasRi-TBRII and
lentiviral RNAi construct pLentiRi-TBRII. These results are
demonstrated in Figures 4 and 5.I nFigure 4, there was
a signiﬁcant decrease of collagen III expression at 24 and
72 hours post-transfection with both constructs in HEK-
293T cells, and there was signiﬁcant inhibition of collagen8 Journal of Biomedicine and Biotechnology
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Figure 3: Gene silencing of TBRII in renal epithelial and ﬁbroblast cells by RNAi. At 24 and 72 hrs post pPlasRi-TBRII and pLentiRi-TBRII
transfection, Western immunoblots for renal ﬁbroblasts (NRK-49F), and epithelial cells (NRK-52E) showed speciﬁc inhibition of TBRII.
Both RNAi plasmids signiﬁcantly inhibited TBRII at 24 and 72 hrs post transfection; however, both ﬁbroblast and epithelial cell lines had
stronger gene silencing with pLentiRi-TBRII at 72 hrs (∗∗P<. 01 and ∗P<. 05, resp., in comparison with controls). Scale bar in each
photomicrograph = 100μM.
III expression in NRK-52E cells at 24 hours (P<. 01).
CollagenIIIinhibitionwasnotapparentat72hoursinNRK-
52E cells. A signiﬁcant decrease of collagen III expression
was also observed in NRK-49F cell lines by lentiviral RNAi
construct at 24 and 72 hours (P<. 01) but not in RNAi
expression construct transfected cells (P>. 05). Fibronectin
expression was signiﬁcantly decreased in HEK-293T, NRK-
52E, and NRK-49F cells at 24 and 72 hours transfection of
either TBRII RNAi expression or lentiviral construct. The
variation in responses of the diﬀerent cell lines, including
the time line responses, underlines the complexity of cellular
contributions to ﬁbrosis and the antiﬁbrotic responses when
planning therapies involving the gene therapies.
There was signiﬁcantly reduced α-SMA expression in
NRK-52EandNRK-49Fcellspost-transfectionofbothRNAi
constructs (Figure 5). Both expression vectors signiﬁcantly
reduced α-SMA expression in NRK-49F cells at 72 hours. In
the NRK-52E cells, α-SMA expression was markedly reduced
atbothtimepoints,althoughthereductioninexpressionwas
most marked with the pLentiRi vector.
4. Discussion
Renal ﬁbrosis is the common pathway of chronic renal
disease that progresses to end-stage kidney disease. Chronic
renal disease is characterized by persistent accumulation and
deposition of ECM which leads to widespread tissue ﬁbrosis
[3, 4, 24]. While progress has been made in delineating
the cellular and molecular pathogenesis during the last
decades, the clinical therapies for chronic renal ﬁbrosis
remain extremely limited. Drug delivery systems that take
advantage of recent RNAi technologies may open new
pathways for therapeutic strategies. In the present study,
a lentiviral construct-mediated RNAi system for posttran-
scriptional, sequence-speciﬁc gene silencing of TBRII for the
treatment of renal ﬁbrosis was demonstrated. Knockdown
of the TBRII gene was observed in cultured renal epithelial
and ﬁbroblast cell lines, and consequently EMT and TGF-
β signalling-regulated ECM accumulation was halted. The
present study demonstrates that the introduction of TBRII
siRNA with lentiviral construct to renal cell populations
can eﬀectively suppress the expression of TBRII. If applied
in disease, this system could limit renal tubulointerstitial
ﬁbrosis.
As a new technology for silencing of a target gene, a
pioneer study in the ﬁeld of renal ﬁbrosis has shown that
siRNA targeting TBRII eﬀectively inhibited renal interstitial
ﬁbrosis by using an RNAi expression construct with cationic
gelatin, in an attempt to overcome the transient, insuﬃcient
transfectioneﬃciencyofchemicallysynthesisedsiRNAs[17].
TBRIIexpressionandα-SMAexpressionweresuppressedfor
up to 10 days in a unilateral ureteral obstruction (UUO)
mouse model. A recent study using TGF-β1 siRNA showed
successful delay of the tubulointerstitial ﬁbrosis process by
evaluatingcollagenaccumulationintheUUOmodelofrenal
ﬁbrosis, in mice [25]. In this study, an RNAi expression
construct processing the U6 RNA promoter, pU6shX, was
employed to demonstrate that RNAi targeting of the TGF-
β signalling pathway could be a valuable tool for prevention
and treatment of renal tubulointerstitial ﬁbrosis.Journal of Biomedicine and Biotechnology 9
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Figure 4:InhibitionofECMbyTBRIIRNAiinrenalcelllines.Westernimmunoblotsofproteinextractsfromhumanembryonickidneycells
(HEK-293T), rat renal ﬁbroblasts (NRK-49F), and epithelial cells (NRK-52E) showed signiﬁcantly reduced ECM production after TBRII
RNAi plasmid transfection (ﬁbronectin is abbreviated as “F’nectin” beside the Western immunoblots). There was signiﬁcantly decreased
collagen III and ﬁbronectin expression post-transfection with pPlasRi-TBRII and pLentiRi-TBRII in NRK-49F and NRK-52E cell lines.
In comparison with pPlasRi-TBRII, pLentiRi-TBRII produced a stronger and longer inhibitory eﬀect on collagen III in NRK-49F and on
ﬁbronectin in all 3 tested cell lines (∗∗P<. 01 and ∗P<. 05 in comparison with controls).10 Journal of Biomedicine and Biotechnology
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Figure 5: Inhibition of α-SMA expression by TBRII RNAiin renal cell lines. Both expression vectors signiﬁcantly reduced α-SMA expression
in renal ﬁbroblasts (NRK-49F) at 72 hrs indicating successful suppression of myoﬁbroblast activation. In the epithelial cells (NRK-52E), α-
SMA expression was markedly reduced with both expression constructs at both time points, indicating inhibition of EMT. The reduction in
expression was most marked with the lentiviral vector. ADU: arbitrary densitometry units.
In the present study, a similar RNAi construct, namely,
pPlasRi, was used with the polymerase III H1-RNA gene
promoter [23, 25, 26]. It produces a small RNA tran-
script lacking a polyadenosine tail and has a well-deﬁned
start of transcription and a termination signal consisting
of ﬁve thymidines in a row [26]. Two pairs of 19-nt
sequence-targeted short hairpin RNAi (shRNAi) cassettes
were designed and cloned into the RNAi expression con-
struct. EGFP was selected as the experimental control
because ﬂuorescence is easy to observe under the ﬂuorescent
microscope and quantiﬁed by FACS analysis [27, 28]. The
result showed satisfactory EGFP suppression of 78.28% at
24 hours. The inhibition eﬀect was however weakened to
69.37% and 40.09% at 48 hours and 72 hours, respectively,
post transfection. This indicated that a gene silencing eﬀect
o fE G F Pc o u l db ea c h i e v e db ya nR N A ie x p r e s s i o nc o n s t r u c t ,
but the eﬀect is transient. Similarly, after construction of
the TBRII RNAi expression construct and its transfection
to HEK-293T cell lines, reduced TBRII expression was most
pronounced at 24 hours post transfection. In comparison
with 48 hours and 72 hours, the transient RNAi eﬀect of the
expression construct was again noted.
In principle, there are two general siRNA delivery
methods. One uses chemically synthesised 19-21nt siRNA
with apparent short-lived eﬀect [28]. The other approach
is vector-based siRNA, including the use of plasmid vectors
and viral vectors. Vector-based siRNA has a more prolonged
eﬀect and is relatively inexpensive. Plasmid-mediated bio-
l o g i c a la c t i v i t yo fR N A is t i l ln e e d st ob ei m p r o v e db yv a r -
ious means. Several synthetic materials, including cationic
liposomes, poly-L-lysine, and PEI, have been molecularly
designed to allow successful transfection of plasmid DNA for
mammalian cells both in vitro and in vivo. In Kushibiki et
al.’s pSUPER TBRII RNAi system, cationic gelatin was used
to facilitate transfection, and it showed relatively satisfactory
gene silencing eﬀect in the UUO model for up to 10 days [5].
Our previous experience indicated that a cationic polymer
PEI could facilitate better transfection than poly-L-lysine
[29], and this was conﬁrmed in the renal cell lines tested.
The results showed that there was RNAi eﬀect on EGFP and
TBRII in both renal epithelial and ﬁbroblast cells after RNAi
expression plasmid transfection.
A prerequisite for developing RNAi-based therapeutics
is an eﬃcient delivery vehicle to transfer the RNAi cassette
into the target cells. Our results demonstrated the transient
nature of the RNAi vectors and the ability of the lentiviral
vector-mediated RNAi system for a sustained transduction
eﬀect, as had been demonstrated previously in terminally
diﬀerentiatedcells[30].Thead vantagesoflenti virusforgene
transfer, especially to non-dividing cells, make the RNAi
technique more accessible for speciﬁc in vitro and in vivo
silencing in renal cell populations. The lentiviral construct
showed signiﬁcant silencing of EGFP in S7 cells. There was
84.17%, 91.57%, and 95.91% decrease of EGFP achieved
at 24 hours, 48 hours, and 72 hours post PEI facilitated
transfection. In comparison with the non-lentiviral RNAi
expression construct, the gene-silencing eﬀect of the lentivi-
ral RNAi construct was stronger and persistent (P<. 01).
TBRII gene silencing in HEK-293T cells showed a similar
result that favoured the lentiviral RNAi construct.Journal of Biomedicine and Biotechnology 11
TBRII expression, ECM production (collagen III,
ﬁbronectin), and marker of EMT (α-SMA expression) were
examined after gene suppression of TBRII. Both constructs
achieved signiﬁcant inhibition with reduced collagen III
and ﬁbronectin expression in HEK-293T, NRK-49F, and
NRK-52E cells, and with the lentiviral RNAi construct
producing a more robust inhibition of ﬁbrogenesis and
continuing inhibition of TBRII 72 hours post-transfection.
Complete TBRII silencing was not achieved, even though a
lentiviral construct was employed, and was facilitated by a
cationic transfection aid PEI. During renal ﬁbrogenesis in
vivo, several events occur in parallel, including an inﬂux
of monocytes/macrophages, activation of myoﬁbroblasts,
accumulation of various ECM proteins, and EMT [31, 32].
As an indicator of ﬁbroblast activation and tubular EMT,
α-SMA expression was evaluated in renal ﬁbroblasts and
epithelial cells. Signiﬁcant reduction of α-SMA was shown
by Western blot analysis, indicating an inhibitory eﬀect on
ﬁbroblast activation and EMT.
5. Conclusion
The present data demonstrated that the lentiviral-mediated
RNAi in renal cell populations was eﬀective not only in
silencing TBRII gene, therefore, blocking TGF-β signalling,
but also modulating activation of ﬁbroblasts, development
of EMT, and reducing ECM accumulation. Successful pro-
longed presence of RNAi in renal cells in vitro was also
demonstrated. The lentiviral RNAi transfection facilitated
by cationic polymer PEI was superior to the classical RNA-
promoter-possessed plasmid-mediated RNAi. Thus, this
technique of delivering RNAi into tubulointerstitial cells
could be a practical therapeutic method for progressive renal
interstitial ﬁbrosis.
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